Certain of the statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, as well as the nucleic acid-based molecular diagnostics and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN’s products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission.

The following slides may contain certain summary information about QIAGEN N.V.’s operating income, net income, and earnings per share, which information is presented on a “non-GAAP financial measures” basis rather than in accordance with U.S. generally accepted accounting principles (“GAAP”). Please review QIAGEN’s recent press releases for information on the company’s gross margin, operating income, net income, and earnings per share for specific periods presented on a GAAP basis. Such GAAP-basis information will also be contained in the company’s reports on Form 20-F and 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission and which are available on QIAGEN’s homepage under www.QIAGEN.com.
As the innovative market and technology leader, QIAGEN creates indispensable solutions that set standards in enabling access to content from any biological sample.

Our mission is to enable our customers to achieve outstanding success and breakthroughs in research, applied markets, drug development and molecular diagnostics. We thereby make improvements in life possible.

Our commitment to the markets we serve drives our innovation and leadership in all areas where solutions such as sample collection, stabilization, separation, purification, storage, handling and processing are required.

The exceptional talent, skill and passion of our employees are key to QIAGEN’s excellence, success and value.

QIAGEN at a Glance

Revenues: 2005: $ 398 million 96–05 CAGR: 25%
Net income: 2005: $ 69 million 96–05 CAGR: 33%¹
EPS: 2005: $ 0.46 96–05 CAGR: 31%¹

Product Range:
- ~500 consumable products
  - Sample Technologies: to collect, separate, purify, stabilize, store, target analytes in samples (DNA, RNA, proteins, etc.)
  - Assay Technologies: to make target analyte visible
- Instrumentation for above consumables

IP (12/05): 409 issued, 321 pending patents >500 under license

Customers >400,000 customers:
- Research: academia, industry (pharma/biotech)
- Applied Testing (vet., forensics, biodefense etc.)
- Molecular Diagnostics

Employees: >1,900 employees based in 29 subsidiaries

¹ excluding acquisition, restructuring and related charges as well as amortization on acquired IP
Focus Provides Strength - New Markets Drive Growth

Sample and Assay Technologies

Technology Leadership

Sales Strength

Growth Drivers

Financials

Focused core competency:
- Sample and assay technologies

Three Markets:
- Life Sciences
  - Academia
  - Pharma
- Applied Testing
  - Forensics
  - Veterinary
  - Other
- Molecular Diagnostics

Sample and Assay Technologies

Pharma 25%
Molecular Diagnostics 25%
Applied Testing 10%
Research 40%

Financials
Did you know that QIAGEN products have been used in preparing more than 950,000,000 nucleic acid samples?
QIAGEN Technology and Innovation Leader

**R&D at QIAGEN:**

- Approx. 10% of sales
- >300 employees in R&D
- Maryland, Germany, Switzerland and China
- Chemistry, biology, physics, engineering and others
- Fast, proven innovation cycles: 4-5% of sales from new products launched in same year
QIAGEN has Significant Marketing and Sales Power

Technology Leadership

Growth Drivers

Sales Strength

Financials

Strong Sales and Marketing Force

Americas
Approx 45% of Sales
Sales and Marketing Force: 258

Europe
Approx 45% of Sales
Sales and Marketing Force: 365

Asia
Approx 10% of Sales
Sales and Marketing Force: 186

~ 800 Sales and Marketing Professionals
– One Clear and Focused Mission
QIAGEN –
One of the Strongest Brands in the Industry

“Which company fits best to these attributes?”

Reliable
Friendly
Competent
Supportive
Respectful
Attentive
Innovative
Fair
Dynamic
Impersonal
Arrogant
Non-responsive

Responses in %

QIAGEN
Competitor

Based on two global surveys (internet and telephone) with more than 5000 participants conducted by an independent agency end of 2005. Companies include: ABI, Bio, Eppendorf, FSH, GE Amersham, IVGN, Promega, Roche DX, SIAL

First Nine Months 2006 Revenue Distribution

Consumables
- Reported growth 17%
- 18% growth CER

Instruments
- 7% growth CER
- 13% growth CER in Q3 2006

Asia
- 37% growth CER
- 66% growth CER in Q3 2006 (driven by China)

RoW (2%)

North America
- 11% growth

Europe
- 19% growth CER

90%
9%
45%
43%
10%

CER = Constant exchange rates
Markets by Customer Groups

Academia (~40% of sales, single digit growth)
- Strong basis
- Key to creating standards in early phases of innovation

Pharma/Biotech (~25% of sales, high growth)
- Preclinical
- Clinical
- Pharmacogenomics

Diagnostics (~25% of revenues, high growth)
- Broadest portfolio of infection disease assays
- Strong brand reputation and presence

Applied Testing (~10% of revenues, high growth)
- Forensics
- Veterinary
- Other: biodefense, food testing, quality control, environmental

QIAGEN is Addressing Key Growth Markets

Technology Leadership

Sales Strength

Growth Drivers

Financials
Announced Today

**SEQUENOM®**

Collaboration targeting molecular diagnostics

- Development of fetal DNA enrichment solution from maternal blood
- for use on Sequenom’s MassARRAY® platform.
- Target: non-invasive prenatal dx (cystis fibosis, Down syndrome, Tay-Sachs syndrome, others)

Addresses biomarker use in pharma and biotech

- QIAGEN: sample and assay technologies
- Pathway: service offering
- Co-development and co-validation of biomarker assays
- Co-promotion of Pathway’s services which are based on QIAGEN sample and assay technologies

Alliance for Pharma customers Pharmacogenomics Molecular diagnostics

---

Disseminating Technologies Into New Markets

**QIAGEN Sample and Assay Technologies**

Common Core Addressing 3 Markets

**Growth Drivers**

- Disseminating Technologies Into New Markets
  - Life Science Research - Academia - Industry
  - Applied Testing
  - Molecular Diagnostics
  - QIAGEN Sample and Assay Technologies
Leveraging Core Competencies

Different Markets – Same Core Competence

QIAGEN – a Leader in Molecular Diagnostics

Estimated 2006 USD Sales in Molecular Diagnostics

<table>
<thead>
<tr>
<th>Company</th>
<th>Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roche</td>
<td>550</td>
</tr>
<tr>
<td>Genprobe</td>
<td>300</td>
</tr>
<tr>
<td>Digene</td>
<td>153</td>
</tr>
<tr>
<td>Bayer</td>
<td>120</td>
</tr>
<tr>
<td>QIAGEN</td>
<td>115</td>
</tr>
<tr>
<td>Abbott</td>
<td>110</td>
</tr>
<tr>
<td>Others</td>
<td></td>
</tr>
<tr>
<td>Cepheid</td>
<td></td>
</tr>
<tr>
<td>Biomerieux</td>
<td></td>
</tr>
<tr>
<td>Becton Dickinson</td>
<td></td>
</tr>
<tr>
<td>Celera Dx</td>
<td></td>
</tr>
<tr>
<td>Beckman</td>
<td></td>
</tr>
<tr>
<td>Innogenetics</td>
<td></td>
</tr>
<tr>
<td>Veridex</td>
<td></td>
</tr>
<tr>
<td>Nanogen</td>
<td></td>
</tr>
<tr>
<td>Third Wave</td>
<td></td>
</tr>
<tr>
<td>Exact</td>
<td></td>
</tr>
<tr>
<td>etc.</td>
<td></td>
</tr>
</tbody>
</table>

Source: company estimates, various industry research reports

QIAGEN is a Leading Player in Molecular Diagnostics
Our offering:
- Sample and Assay Technologies
- Capabilities
- IP

Our channels:
- Dx sales channels
- Strong brand
- Customer service
- Established networks in R&D and Marketing

Operations:
- QC
- Regulatory
- Logistics

R&D:
- Leading and large assay development teams
- Integration with preanalytical
- Automation

Molecular Diagnostics Growth Strategy

Direct Sales
- Growing direct sales force > 40
- No instrument dependency
- Focus on pathogens
- Market leader in developing countries

OEM Products
- Integrated solutions, CE and FDA
- Assays, preanalytical, automation
- > 15 Partners
- > 100 clinical trials using QIAGEN
- > 50 clinical trials using PreAnalytiX

OEM development
- Developing solutions for partners
Sample and Assay Technologies

Genaco
Patented Breakthrough in Multiplexing in MDx

Assay design technology to detect dozens of targets in one assay with breakthrough sensitivity and specificity

Acquired in Q4 2006 for $22 million in cash plus milestones

Complementary to QIAGEN’s MDx assay portfolio
- Multiplexing links with QIAGEN qPCR tests
- Focus on infectious diseases
- Multiplexing emerging trend in MDx

Genaco products employ
- QIAGEN sample technology
- QIAGEN PCR assay technologies

Solid intellectual property, best in class technology
- Pre- IDE filed with FDA – pathway to H5N1 510k

Milestone in Expanding MDx Leadership

---

Genaco
Patented Breakthrough in Multiplexing in MDx

Sample and Assay Technologies

Single Analyte qPCR Testing to Confirm Infection

Potential Pathogens

Syndrome “Patient Presentation”

Selection of test for one potential pathogen

Confirmed Pathogen ID

Potential Issue: If result is negative, no diagnosis made for patient
**Multiplexing – To Identify Unknown Pathogen**

Potential Pathogens

- SARS
- Avian Flu
- RSV
- RSVB
- hMPV
- PIVI
- PIVII
- Ent
- Rhino
- Coxsackie

Syndrome “Patient Presentation”

- Respiratory Syndrome

Multiplex Panel

- RSVB

Selection of test for one potential pathogen

- Confirmed Pathogen ID

Selected qPCR Test

- qPCR: High resolution confirmation/quantification

Multiplexing: Screening technology

Growth Drivers

**QIAGEN’s M&A Strategy**

Creating Preanalytical Solutions for Systems Biology

Disseminating Reach of Core Capabilities

2005 Eppendorf 5-Prime

2005 LumiCyte, Inc.

2006 Gentra

2006 RNASure

2005 Tianwei Times

2005 PG Biotech Co. Ltd.

2006 artus GmbH

2005 SuNyx GmbH

2005 Nextal Biotechnologies

2005 RNAture

QIAGEN’s M&A Strategy
Sample and Assay Technology Leadership

- Leadership in sample technologies
- Leadership in assay technologies
- Innovation leader
- Focus area addresses rapid growth markets
  - Molecular diagnostics
  - Applied Testing
- Strong base in Life Science Research -> standards

Sample and Assay Technologies

QIAGEN 2006

Strong Financial Base – Exciting Model

Technology Leadership

Sales Strength

Financials

Growth Drivers
QIAGEN Revenue Recognition 2003 – 2006E

US$ millions

3-year CAGR* = 14%
*CAGR 2003-2005

QIAGEN – Continuous Double Digit Revenue Growth Rates

- Revenues excluding the synthetic DNA business unit, sold in Q2 2004
- 2006 figures based on guidance provided by the company on May 9, 2006

QIAGEN Operating Margins 2003 – 2006E

% of revenues

2003 2004 2005 2006E

QIAGEN – Strong Operating Margin Increases

- All figures excluding acquisition, integration and relocation related charges as well as amortization of acquired IP and equity-based compensation (SFAS 123R)
- 2006 figures based on guidance provided by the company on May 9, 2006
QIAGEN Net Income 2003 – 2006E

3-year CAGR* = 22%
* CAGR 2003-2005

US$ millions

2003  2004  2005  2006E
30  50  70  90

QIAGEN – Strong Earnings Engine

QIAGEN First Nine Months 2006 at a Glance

In US$ millions unless indicated

<table>
<thead>
<tr>
<th></th>
<th>Target1</th>
<th>Reported</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales</td>
<td>324-333</td>
<td>340</td>
<td>Exceeded</td>
</tr>
<tr>
<td>Operating margin, adj.2</td>
<td>25-27%</td>
<td>26%</td>
<td>In line</td>
</tr>
<tr>
<td>EPS, adj. (US$)3</td>
<td>0.36-0.39</td>
<td>0.40</td>
<td>Exceeded</td>
</tr>
</tbody>
</table>

Cash EPS2

0.30

1 based on quarterly guidance communicated by the company on May 9th
2 excluding acquisition, integration and relocation related charges as well as amortization of acquired IP and equity-based compensation (SFAS 123R)
3 computed using net cash provided by operating activities divided by number of fully diluted shares

QIAGEN Well on Track to Achieve Full Year Guidance
### Third Quarter Contributions to Growth

<table>
<thead>
<tr>
<th></th>
<th>Actual</th>
<th>CER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consumables</td>
<td>20%</td>
<td>18%</td>
</tr>
<tr>
<td>Instruments</td>
<td>15%</td>
<td>13%</td>
</tr>
<tr>
<td>Other</td>
<td>15%</td>
<td>11%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>20%</td>
<td>17%</td>
</tr>
<tr>
<td><strong>Acquisitions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consumables</td>
<td>7%</td>
<td>7%</td>
</tr>
<tr>
<td>Instruments</td>
<td>6%</td>
<td>6%</td>
</tr>
<tr>
<td>Other</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>7%</td>
<td>7%</td>
</tr>
<tr>
<td><strong>Organic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consumables</td>
<td>11%</td>
<td></td>
</tr>
<tr>
<td>Instruments</td>
<td>7%</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>11%</td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>10%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>CER = Constant exchange rates</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Demonstrating Strong Organic Growth in Consumables of 11% and 10% Organic Growth Overall</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Summary

**Strong first nine months 2006**
- Exceeded 9M revenue targets
- EPS YTD 21% growth compared to 2005
- Operating income margin (adj.) 26%
- Well on track to achieve full year guidance

**Strategic positioning and momentum strong**
- Molecular diagnostics
- Applied testing
- Focused on core competencies
- Present in key markets direct (i.e. 2005/06 Asia expansion)

**Strong growth engine**
- Developed: 53 launches in 06 -> 4-5% of sales
- Partnered: >50 academic, >50 commercial partnerships
- Acquired:
  - Gentra – large volume sample tech (Q2 06)
  - Genaco – multiplexing assay tech (Q4 06)

**Executing on Plans – Expanding – Setting Standards**